Brief: Cyteir Therapeutics Shares Open 8.3% Below IPO Price In Market Debut
June 18 (Reuters) -
* CYTEIR THERAPEUTICS SHARES OPEN AT $16.50 IN DEBUT ON
NASDAQ
VERSUS IPO PRICE OF $18.00/SHARE
Further company coverage: CYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyteir Therapeutics
See all newsBrief: Cyteir Announces Timeline For Voluntarily Delisting From Nasdaq
Brief: Cyteir Therapeutics Timothy Romberger Resigned From Board & All Of Its Committees
Brief: Ongoing Results From A Dose Expansion Cohort Of Cyt-0851 In Combination With Capecitabine In Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity And Generally Well Tolerated Safety Profile
Brief: Cyteir Therapeutics Announces Discontinuation Of Cyt-0851 Development Program And Planned Liquidation And Dissolution
Brief: Cyteir Says Preliminary Ongoing Results With CYT-0851 In Combination With Capecitabine Or Gemcitabine In Advanced Solid Tumors Show Early Clinical Activity And Generally Well Tolerated Safety Profile